Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423520 | 0.85 | PLG (0.44) | LMNAACHEL3MBTL1KIF11TBK1 | |
| SCHEMBL23877038 | 0.81 | CYP2A6 (0.41) | LMNAACHEL3MBTL1NPC1RAB9A | |
| SCHEMBL10057582 | 0.81 | CYP2A6 (0.50) | LMNAACHEL3MBTL1KIF11TBK1 | |
| SCHEMBL17962938 | 0.80 | PLAU (0.47) | LMNAACHEL3MBTL1GSK3BCDK5 | |
| SCHEMBL12546016 | 0.80 | ROCK1 (0.53) | TBK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL20441667 | 0.80 | TRPA1 (0.40) | LMNAACHEL3MBTL1KIF11TBK1 | |
| SCHEMBL26497718 | 0.80 | TBK1 (0.38) | LMNAACHEL3MBTL1KIF11TBK1 | |
| SCHEMBL22170802 | 0.80 | LMNA (0.40) | LMNAACHEL3MBTL1KIF11TBK1 | |
| SCHEMBL6380931 | 0.79 | TRPA1 (0.43) | ACHEL3MBTL1TBK1AURKADAPK3 | |
| SCHEMBL18431778 | 0.77 | GRM4 (0.41) | LMNAACHEL3MBTL1KIF11TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-10407421-B2 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX, INC. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX, INC. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-9556144-B2 | Compound as WNT signaling inhibitor, composition, and use thereof | CUREGENIX, INC. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160000780-A1 | Compounds for Treatment of Cancer | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX INC. (CN) | 2015-04-30 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120039847-A1 | Hepatitis C Virus Inhibitors | ZHAO SHU-HAI (CN) | 2012-02-16 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407421-B2 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MGAM, BMX, XDH | LMNA 1090/4885ACHE 1971/4885L3MBTL1 455/4885 |
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, WNT3A, WNT3 | LMNA 2988/4885ACHE 2714/4885L3MBTL1 2526/4885 |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | LMNA 3441/4885ACHE 4735/4885L3MBTL1 4145/4885 |
| US-20120039847-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, LIPC | LMNA 3321/4885ACHE 3588/4885L3MBTL1 4378/4885 |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | LMNA 2983/4885ACHE 2835/4885L3MBTL1 3832/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | LMNA 792/4885ACHE 4806/4885L3MBTL1 127/4885 |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, SFRP1, WNT3 | LMNA 2744/4885ACHE 4668/4885L3MBTL1 3091/4885 |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | LMNA 2902/4885ACHE 3079/4885L3MBTL1 3619/4885 |
| US-20160000780-A1 | Compounds for Treatment of Cancer | WNT1, CTNNB1, WNT3 | LMNA 3824/4885ACHE 4598/4885L3MBTL1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.